ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway

Cheng, Yanzhen; Liu, Peng; Xiang, Qianru; Liang, Jiamin; Chen, Huafeng; Zhang, Hua*; Yang, Li*南方医科大学
BMC MUSCULOSKELETAL DISORDERS2022-5-17DOI: 10.1186/s12891-022-05396-5
4被引18阅读
引用收藏
分享

摘要

Background Diabetes-associated osteoporosis are partly caused by accumulation of advanced glycation endproducts (AGEs). Glucagon-like peptide-1 (GLP-1) has been shown to regulate bone turnover. Here we explore whether GLP-1 receptor agonist (GLP1RA) can have a beneficial effect on bone in diabetes by ameliorating AGEs. Methods In the present study, we evaluated the effects of the GLP-1 receptor agonist liraglutide, insulin and dipeptidyl peptidase-4 inhibitor saxagliptin on Zucker diabetic fatty rats. Meanwhile, we observed the effect of GLP-1 on AGEs-mediated osteoblast proliferation and differentiation and the signal pathway. Results Liraglutide prevented the deterioration of trabecular microarchitecture and enhanced bone strength. Moreover, it increased serum Alpl, Ocn and P1NP levels and decreased serum CTX. In vitro we confirmed that GLP-1 could attenuate AGEs-mediated damage in osteogenic proliferation and differentiation. Besides, GLP-1 down-regulated the ROS that caused by AGEs and the mRNA and protein expression of Rage . Conclusions Altogether, our findings suggest that GLP-1 receptor agonist promotes osteoblastogenesis and suppresses bone resorption on obese type 2 diabetic rats to a certain degree. The mechanism of these effects may be partly mediated by AGEs-RAGE-ROS pathway via the interaction with GLP-1 receptor.

学科与关键词

关键词
Glucagon-like peptide-1Advanced glycation endproductsDiabetesOsteoporosisLiraglutide
相关
加载中…
  • The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Bone Metabolism and Its Possible Mechanisms in Osteoporosis Treatment
    Xie, Baocheng; Chen, Shichun; Xu, Yongxiang; Han, Weichao; Hu, Runkai; Chen, Minyi; Zhang, Yusheng*; Ding, Shaobo*Frontiers in Pharmacology, 2021, 12: 697442.被引 19
  • Liraglutide Alleviates Diabetic Atherosclerosis through Regulating Calcification of Vascular Smooth Muscle Cells
    Shi, Li-Li; Hao, Ming; Jin, Zhou-Yun; Peng, Gui-Fang; Tang, Ying-Ying*; Kuang, Hong-Yu*DISEASE MARKERS, 2022, 2022: 5013622.被引 5
  • Exendin-4 promotes bone formation in diabetic states via HDAC1-Wnt/β-catenin axis
    Deng, Ying; Zhu, Wenyi; lin, Anhua; Wang, Chenxiu; Xiong, Changhui; Xu, Fanghua; Li, Jinfeng; Huang, Shuijin; Zhang, Na; Huo, Yanan*Biochemical and Biophysical Research Communications, 2021, 544: 8-14.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC MUSCULOSKELETAL DISORDERS
发表日期
2022-05-17
卷期
第 23 卷, 第 1 期
页码
465
DOI
10.1186/s12891-022-05396-5
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81500679]; Natural Science Foundation of Guangdong Province, China [2017A030313519]; Science and Technology Plan of Guangdong Province [2017A020215045]; Science and Technology Plan of Guangzhou [202102020165]; Guangdong Basic and Applied Basic Research Foundation [2020A1515010288, 2021A1515220101]

作者

  • C

    Cheng, Yanzhen (第一作者)

    2 · southern med univ

  • L

    Liu, Peng

    2 · southern med univ

查看全部 7 位作者收起作者
  • X

    Xiang, Qianru

    2 · southern med univ

  • L

    Liang, Jiamin

    2 · southern med univ

  • C

    Chen, Huafeng

    2 · southern med univ

  • Z

    Zhang, Hua (通讯)

    2 · southern med univ

  • Y

    Yang, Li (通讯)

    2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417